Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.
Last trade$4.67
Day change+$0.1204 (+2.65%)
Day range$4.28 – $4.75
Volume16,886
Market cap$37M
OpenXASE
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$36.69M
Price / earnings
—
Price / book
-2.24×
Price / sales
1.18×
EV / sales
1.43×
EV / EBITDA
8.05×
Profitability
Earnings per share
-$0.24
Return on assets
-3.12%
Return on equity
11.87%
Dividend yield
0%
Liquidity and leverage
Debt / equity
-0.56×
Current ratio
0.86×
Quick ratio
0.82×
Cash ratio
0.09×
Cash flow
Price / cash flow
7.46×
Price / free cash flow
7.89×
Free cash flow
$4.65M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for CCEL, quarterly periods
Line item
Q3 FY2026 Aug 31, 2026
Q2 FY2026 May 31, 2026
Q1 FY2026 Feb 28, 2026
Q4 FY2025 Nov 30, 2025
Q3 FY2025 Aug 31, 2025
Q2 FY2025 May 31, 2025
Q1 FY2025 Feb 28, 2025
Q4 FY2024 Nov 30, 2024
Revenue
$7.82M
$7.78M
$7.68M
$7.84M
$7.83M
$7.93M
$7.97M
$8.02M
Cost of revenue
$1.61M
$1.68M
$1.66M
$1.73M
$1.8M
$1.86M
$1.98M
$1.64M
Gross profit
$6.21M
$6.1M
$6.03M
$6.11M
$6.02M
$6.07M
$5.98M
$6.39M
Selling, general and administrative
$3.78M
$4.62M
$5.01M
$5.45M
$3.88M
$4.26M
$4.64M
$6.01M
Research and development
$53.62K
$99.78K
$65.76K
$84.78K
$61.63K
$131.71K
$98.14K
$304.63K
Total operating expenses
$4.02M
$4.9M
$5.26M
$10.08M
$4.12M
$4.58M
$4.93M
$6.2M
Operating income
$2.19M
$1.2M
$765.13K
-$3.97M
$1.9M
$1.49M
$1.06M
$185.65K
Interest expense
-$438.31K
-$441.92K
-$462.71K
-$481.95K
-$538.22K
-$551.13K
-$494.96K
-$745.49K
Income before taxes
$1.83M
$827.78K
$70.31K
-$4.63M
$1.19M
$575.1K
$533.72K
-$842.43K
Income taxes
$554.96K
$273.2K
$23.2K
-$814.54K
$436.59K
$219.32K
$250.86K
$1.02M
Net income
$1.27M
$554.59K
$47.11K
-$3.82M
$749.41K
$355.79K
$282.86K
-$1.86M
Net income attributable to common shareholders
$1.27M
$554.59K
$47.11K
-$3.82M
$749.41K
$355.79K
$282.86K
-$1.86M
EBITDA
$2.43M
$1.44M
$1.01M
$635.06K
$2.14M
$1.74M
$1.3M
$434.65K
Basic earnings per share
$0.16
$0.07
$0.01
-$0.47
$0.09
$0.04
$0.03
-$0.23
Diluted earnings per share
$0.16
$0.07
$0.01
-$0.48
$0.09
$0.04
$0.03
-$0.23
Recent news
Company coverage with links to the original publishers.
The global cord blood banking services market is projected to grow from USD 33.85 billion in 2025 to USD 49.85 billion by 2031, with a CAGR of 6.84%. Growth is driven by increasing awareness of stem cell therapies, advancements in regenerative medicine, and expanding clinical applications in treating hematological and genetic disorders. North America leads with 39.54% market share, while Asia-Pacific emerges as a high-growth region.
The global stem cell banking market is projected to reach $18.65 billion by 2031, growing at a CAGR of 18.30% due to advancements in cryopreservation, cell bank preparation, and the rising adoption of stem cell therapy. The market is driven by increased awareness of stem cell therapy, growing healthcare investments, and trends in personalized medicine.
The global stem cell banking market is expected to reach a value of USD 18.65 Billion by 2031, growing at a CAGR of 18.30% during the forecast period. The market is driven by advancements in cryopreservation, increased application of stem cell treatments, and the trend of late parenting leading to interest in cord blood banking.
OLDSMAR, Fla., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for its fiscal year ended November 30, 2022.
OLDSMAR, Fla., Oct. 14, 2022 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal third quarter ended August 31, 2022.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
Ex-dividend
Amount / share
Pay date
Type
May 21, 2025
$0.15
May 30, 2025
recurring
Feb 14, 2025
$0.25
Feb 28, 2025
recurring
Nov 15, 2024
$0.25
Nov 29, 2024
recurring
Stock splits
Historical share-structure events and their execution dates.